lamivudine has been researched along with abacavir in 371 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (3.50) | 18.2507 |
| 2000's | 198 (53.37) | 29.6817 |
| 2010's | 133 (35.85) | 24.3611 |
| 2020's | 27 (7.28) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, Y; Choo, H; Chu, CK | 1 |
| Agrawal, B; Johar, M; Kumar, R; Semaine, W; Tyrrell, DL | 2 |
| Haefeli, WE; Ketabi-Kiyanvash, N; Lindenmaier, H; Theile, D; Weiss, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ainsworth, J; Booth, C; Bradshaw, D; Geretti, AM; Malik, S; Pattery, T; Van Houtte, M; Waters, A | 1 |
| Anderson, DJ; Gottlieb, GS; Preston, BD; Pyrak, CL; Smith, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Agrawal, B; Kumar, R; Mak, M; Shakya, N; Srivastav, NC; Tyrrell, DL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Balzarini, J; Bourdin, C; Chamberlain, S; Derudas, M; Hamon, N; Hinsinger, K; Introini, A; Kandil, S; Kolykhalov, A; Madela, K; Margolis, L; McGuigan, C; Meneghesso, S; Pertusati, F; Serpi, M; Slusarczyk, M; Vanpouille, C; Vernachio, J | 1 |
| Arumugam, SR; Badri, KR; He, JJ; Visalli, RJ; Zhang, X; Zhao, H; Ziobrowski, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Hoetelmans, RM; Jurriaans, S; Lange, JM; Lukashov, VV; Notermans, DW; Prins, JM; Roos, M; Schuitemaker, H; Weverling, GJ | 1 |
| Saag, MS; Schooley, RT | 1 |
| Cutrell, A; Harrer, T; Harrigan, RP; Katlama, C; Lanier, RE; Massip, P; Pearce, G; Staszewski, S; Steel, H; Tortell, SM; Yeni, P | 1 |
| Chittick, GE; McDowell, JA; Wang, LH | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Staszewski, S | 1 |
| Gendelman, HE; Lanier, ER; Limoges, J; McClernon, DR; Persidsky, Y; Poluektova, L; Rasmussen, J; Ratanasuwan, W; Zelivyanskaya, M | 1 |
| Ait-Khaled, M; Cutrell, A; Griffin, P; Harrigan, R; Katlama, C; Mesogiti, D; Miller, V; Pearce, G; Staszewski, S; Stone, C; Tisdale, M | 1 |
| Bernasconi, E; Carota, A; Magenta, L; Moccetti, T; Piffaretti, JC | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Babiker, A; de Rossi, A; Gibb, DM; Grosch-Woerner, I; Klein, N; Newberry, A | 1 |
| Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
| Burger, DM; Hoetelmans, RM; Jurriaans, S; Lange, JM; Portegies, P; Prins, JM; Sommadossi, JP; Turner-Foisy, ML; van Praag, RM; Weverling, GJ; Zhou, XJ | 1 |
| Binley, JM; Clas, B; Hurley, A; Ketas, T; Little, S; Markowitz, M; Moore, JP; Richman, D; Schiller, D; Trkola, A | 1 |
| Dechant, C; Goldwich, A; Grunke, M; Harrer, T; Kalden, JR; Kasten, S; Rascu, A; Schmitt, M | 1 |
| Degen, O; Stellbrink, HJ; van Lunzen, J | 1 |
| Church, JA; Cutrell, A; Emmanuel, P; Hetherington, S; Mitchell, C; Nelson, RP; Richardson, CG; Sáez-Llorens, X; Sleasman, J; Spreen, W; Van Dyke, R; Wiznia, A | 1 |
| Kerr, C | 1 |
| Bellman, PC; Fisher, RL; Henry, K; Liao, Q; Norris, D; Ross, LL; Shaefer, MS; Wallace, RJ | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Goh, LE; Grey, P; Kaufmann, GR; Smith, D; Suzuki, K; Zaunders, JJ | 1 |
| Thompson, CA | 1 |
| Brotas, V; Cooper, D; Cutrell, A; Gathe, J; Hammer, SM; Hetherington, S; Hicks, C; Isaacs, R; Johnson, M; Keiser, P; Montaner, J; Raffi, F; Spreen, W; Staszewski, S; Steel, H; Thorborn, D; Tortell, S | 1 |
| Loveday, C | 1 |
| Allsup, TL; Hutman, HW; Lou, Y; Mahony, WB; Otto, VR; Thompson, NF; Yuen, GJ | 1 |
| Crémieux, AC; Demarles, D; Gillotin, C; Katlama, C; Raffi, F; Yuen, GJ | 1 |
| Caldwell, P; Furlan, S; Ho, D; Hurley, A; Johnson, J; Kost, RG; Markowitz, M; Smiley, L; Talal, A; Vesanen, M; Zhang, L | 1 |
| Hanna, L | 1 |
| Bentata, M; David, F; Delfraissy, JF; Katlama, C; Lanier, ER; Mamet, JP; Massip, P; Rozenbaum, W; Trepo, C; Vavro, C; Zucman, D | 1 |
| Angelini, E; Chêne, G; Clavel, F; Ferchal, F; Maillard, A; Molina, JM; Picard, V; Race, E | 1 |
| Bisset, LR; Böni, J; Hofmann-Lehmann, R; Lüthy, R; Lutz, H; Schüpbach, J | 1 |
| Korn, K; Schmidt, B; Schwingel, E; Walter, H; Werwein, M | 1 |
| Fischl, MA; Gao, H; Gensler, T; Graham, NM; Hernandez, JE; Hessenthaler, SM; Kirkland, LR; McClernon, DR; Paar, D; Pittman, G; Rosenzweig, JR; Tashima, KT | 1 |
| Henry, K; Jenny-Avital, E | 1 |
| Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
| Andersson, J; Cooper, D; Goh, LE; Hoen, B; Janossy, G; Kinloch, S; Lampe, F; Perrin, L; Tilling, R; Tsoukas, C; Zaunders, J | 1 |
| Gazzard, BG; Moyle, GJ | 1 |
| de Wolf, F; Jurriaans, S; Lange, JM; Prins, JM; van Praag, RM; Wit, FW | 1 |
| Perrin, L | 1 |
| Battegay, M; Bernasconi, E; Bisset, LR; Chave, JP; Fischer, M; Furrer, H; Günthard, H; Hirschel, B; Howe, C; Lazzarin, A; Ledergerber, B; Opravil, M; Perrin, L; Vernazza, P; Weber, R; Yerly, S | 1 |
| Ait-Khaled, M; Clumeck, N; Cutrell, A; Fischl, MA; Gould, J; Greenberg, SB; Griffin, P; Lafon, S; Pearce, G; Peters, BS; Pulido, F; Rakik, A; Rubio, R; Spreen, W; Tisdale, M | 1 |
| Báez, C; Castaño, E; Castrejón, MM; Danehower, S; De Suman, O; Hetherington, S; Keller, A; Lanier, ER; McClernon, D; McCoig, C; Ramilo, O; Redondo, W; Richardson, C; Sáez-Llorens, X | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y | 1 |
| Almond, LM; Back, DJ; De Vries, C; Gould, J; Hoggard, PG; Kewn, S; Khoo, SH; Lou, Y; Maherbe, A; Sales, SD; Wood, R | 1 |
| Ait-Khaled, M; Babiker, AG; Compagnucci, A; De Rossi, A; Dunn, DT; Gibb, DM; Kaye, S; Loveday, C; Muñoz-Fernandez, MA; Pillay, D; Walker, AS | 1 |
| Bodasing, N; Fox, R; Gourlay, Y; Peters, SE; Seaton, RA | 1 |
| Arnaud, A; Mauboussin, JM; Peyrière, H; Rouanet, I; Vincent, D | 1 |
| Everall, IP; Foster, R; Olajide, D | 1 |
| James, JS | 1 |
| Arici, C; Callegaro, A; Goglio, A; Gregis, G; Maggiolo, F; Quinzan, G; Ripamonti, D; Suter, F; Tebaldi, A | 1 |
| Aquilina, C; Boué, F; Brun-Vezinet, F; Descamps, D; Goetschel, A; Lafeuillade, A; Livrozet, JM; Mamet, JP; Matheron, S; Thiaux, C; Troisvallets, D | 1 |
| Ibbotson, T; Perry, CM | 1 |
| Addison, WR; Allen, MI; Condreay, LD; Tipples, GA; Tyrrell, L; Walters, KA | 1 |
| Chakraborty, R; Cross, A; D'Agostino, A; Musoke, R; Palakudy, T | 1 |
| Herrmann, SE; James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB; Nolan, DA; White, AJ | 1 |
| Cuadrado Pastor, JM; Fernández Villalba, E; Pardo López, MA; Pérez Hervás, MP | 1 |
| Derse, D; Hill, SA; Lloyd, PA; McDonald, S; Wykoff, J | 1 |
| Brown, LS; Crawford, KH; Farthing, CF; Goodwin, SD; Racine, J; Rawlings, MK; Scott, RC; Shaefer, MS; Thompson, MA; Tolson, JM; Williams, VC | 1 |
| Bouhour, D; Dumouchel-Champagne, H; Durupt, F; Ferry, T; Granier, P | 1 |
| Barber, RE; Lonergan, JT; Mathews, WC | 1 |
| Bellos, NC; Burnside, AE; Farthing, CE; Fischl, MA; Kauf, TL; Shaefer, MS; Thompson, MA; Wannamaker, PG; Williams, VC | 1 |
| Moyle, GJ | 2 |
| Becker, S; Feinberg, J | 1 |
| Feinberg, J | 2 |
| Brinkman, K; Frissen, PH; Hoogewerf, M; Regez, RM; Schouten, WE; Weigel, HM | 1 |
| Danner, SA; Gruzdev, B; Jurriaans, S; Lange, JM; Peeters, M; Prins, JM; Rakhmanova, A; Sankatsing, SU; van't Klooster, G; Weverling, GJ | 1 |
| Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J | 1 |
| Gallant, JE | 1 |
| Erbelding, EJ | 1 |
| Boghossian, J; Gray, GE; Millard, JM; Nadler, JP; Quinones, AR; Rodriguez-French, A; Sepulveda, GE; Wannamaker, PG | 1 |
| Hernández-Quero, J; Martínez-Ramírez, M; Muñoz-Medina, L; Parra-Ruiz, J; Serrano-Falcón, C | 1 |
| Boyle, BA | 1 |
| Antoniou, T; Arbess, G; Gough, K; Yoong, D | 1 |
| Ait-Khaled, M; Craig, C; Griffin, P; Stone, C; Tisdale, M | 1 |
| Acosta, EP; Gulick, RM; Klingman, KL; Kuritzkes, DR; Lustgarten, S; Maher, WE; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Shikuma, CM; Snyder, S; Squires, KE; Witt, MD | 1 |
| Cardiello, P; Cooper, DA; Emery, S; Juengprasert, N; Kroon, ED; Lange, JM; Phanuphak, P; Ratanasuwan, W; Ruxrungtham, K; Siangphoe, U; Srasuebkul, P; Tongtalung, M; Ubolyam, S; Ungsedhapand, C | 1 |
| Cahn, P; Carosi, G; Jordan, JC; Montroni, M; Pearce, G; Pharo, CE; Schechter, M; Smaill, F; Soto-Ramirez, L; Thomas, NE; Vibhagool, A | 1 |
| Cahn, P; Carosi, G; Jordan, JC; Pharo, CE; Schechter, M; Smaill, F; Soto-Ramirez, L; Steel, HM; Thomas, NE; Vibhagool, A | 1 |
| Cao, Y; McCoig, CC; Ramilo, O; Saavedra-Lozano, J; Vitetta, ES | 1 |
| De Luca, A; Di Giambenedetto, S | 1 |
| Maida, I; Nuñez, M; Soriano, V | 1 |
| Bernard, E; Del Giudice, P; Dellamonica, P; Marq, L; Perrin, C; Vandenbos, F | 1 |
| Bonny, T; Brand, JD; Brothers, CH; Buendia, CB; Castillo, SA; DeJesus, E; Gerstoft, J; Hernandez, J; Herrera, G; Lanier, ER; Scott, TR; Teofilo, E | 1 |
| Ait-Khaled, M; Gibb, D; Givens, N; Griffin, P; Irlbeck, D; Lanier, ER; St Clair, M; Stone, C; Tisdale, M; Underwood, M; Walker, S | 1 |
| Bassetti, D; Bassetti, M; Briozzo, A; Cruciani, M; Di Biagio, A; Ferrazin, A; Gatti, G; Rosso, R | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Lagathu, C; Lombès, A; Walker, UA | 1 |
| Baumann, D; Bernasconi, E; Blasko, M; Calmy, A; Chave, JP; Furrer, H; Ledergerber, B; Opravil, M; Perrin, L; Vernazza, P | 1 |
| Bower, M; Fisher, M; Gazzard, B; Johnson, M; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Orkin, C; Stebbing, J | 1 |
| Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Marzocchetti, A; Pompucci, A; Scoppettuolo, G; Tumbarello, M; Vago, G | 1 |
| Dando, TM; Scott, LJ | 1 |
| Ibarra Barrueta, O; Iglesias Lambarri, A; Illaro Uranga, A; Lertxundi Etxebarría, U; Martínez Bengoechea, MJ; Santos Ibáñez, A | 1 |
| Aarnoutse, RE; Burger, DM; Verweij-van Wissen, CP | 1 |
| Bartsch, G; El-Sadr, WM; Gibert, C; Grunfeld, C; Kotler, D; Peng, G; Raghavan, S; Shlay, JC; Visnegarwala, F; Wang, J | 1 |
| del Rio, C | 1 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Cahn, P; Castillo, SA; Craig, C; DeJesus, E; Gordon, DN; Moyle, GJ; Scott, TR; Zhao, H | 1 |
| Farthing, C; Guyer, B; Khanlou, H | 1 |
| Farthing, C; Guyer, B; Khanlou, H; Yeh, V | 1 |
| Bergshoeff, A; Burger, D; Farrelly, L; Flynn, J; Gibb, D; Khoo, S; Le Prevost, M; Lyall, H; Novelli, V; Verweij, C; Walker, S | 1 |
| D'Agostino, C; d'Ettorre, G; Lichtner, M; Massetti, AP; Mastroianni, CM; Vullo, V | 1 |
| Borroto-Esodo, K; Eisenberg, EJ; Fridland, A; Miller, MD; Myrick, F; Olson, LY; Ray, AS; Vela, JE | 1 |
| Davis, EA; DeJesus, E; Hill-Zabala, C; Lang, J; Lanier, ER; Liao, Q; Markowitz, M; Shaefer, M | 1 |
| Bonjoch, A; Clotet, B; De la Torre, J; Galvez, J; Martínez, E; Miralles, C; Miranda, J; Muñoz-Moreno, JA; Paredes, R; Prieto, A; Videla, S; Vilades, C | 1 |
| Brun-Vézinet, F; Collin, G; Delaunay, C; Descamps, D; Flandre, P; Landman, R; Miller, M; Peytavin, G; Trylesinski, A | 1 |
| Freeman, A; Harvey, R; Hazen, R; Lanier, ER; Ross, L | 1 |
| Kuritzkes, DR | 1 |
| Berger, DS; Gallant, JE; Johnson, J; Liao, Q; Lim, ML; Rodriguez, AE; Ross, L; Shaefer, MS; Weinberg, WG; Young, B | 1 |
| Billaud, E; Bugnon, F; Cua, E; Cuzin, L; Dellamonica, P; Delpierre, C; Massip, P; Pugliese, P; Raffi, F | 1 |
| Dejesus, E; Florance, A; Herrera, G; Hill-Zabala, C; Shaefer, M; Sosa, N; Vavro, C; Watson, M | 1 |
| Anderson, AM; Bartlett, JA | 1 |
| Bellón, JM; Berenguer, J; Camba, M; Flores, J; Gatell, JM; Hernández-Quero, J; Knobel, H; Miguélez, M; Pérez-Elías, MJ; Podzamczer, D; Resino, S; Rivas-González, P; Sala, M; Santos, I; Soriano, V | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| Clumeck, N; Craig, C; Domingo, P; Fu, K; Gordon, D; Lamarca, A; Plettenberg, A; Scott, T; Watson, M; Zhao, H | 1 |
| Carr, A | 1 |
| Burger, DM; Clapson, M; Farrelly, L; Flynn, J; Gibb, DM; Green, H; Head, S; LePrevost, M; Lyall, H; Novelli, V; Walker, AS | 1 |
| DeJesus, E; Eron, J; Estrada, V; Gathe, J; Katlama, C; Lackey, P; Patel, L; Shaefer, M; Staszewski, S; Sutherland-Phillips, D; Vavro, C; Wannamaker, P; Yau, L; Yeni, P; Yeo, J; Young, B | 1 |
| Acosta, EP; Bastow, B; Carlson, M; Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, C; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Brothers, CH; Castillo, SA; Hernandez, JE | 1 |
| Margot, NA; Miller, MD; Waters, JM | 1 |
| Farthing, C; Khanlou, H | 1 |
| Antonelli, G; Baranello, C; Bellomi, F; Falasca, F; Focher, F; Morgan, J; Pagnotti, P; Pierangeli, A; Schuetz, JD; Turriziani, O | 1 |
| Mellors, JW; Parikh, UM; Sheen, CW; Sluis-Cremer, N; Torres, PS; Zelina, S | 1 |
| Alonso, C; Aranda, M; Barrufet, P; Berenguer, J; Crespo, M; del Río, L; Delegido, A; Ferrer, E; Fisac, C; Gatell, JM; Lérida, A; Llibre, JM; Lonca, M; Martínez-Lacasa, J; Merino, E; Niubo, J; Pedreira, JD; Podzamczer, D; Pulido, F; Ribas, MA; Ribera, E; Rubio, R; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Moyle, G; Waters, L | 1 |
| Neal, EF; Poston, PA; Robbins, BL; Rodman, JH; Slaughter, C | 1 |
| Bastow, B; Glesby, MJ; Gulick, RM; Kuritzkes, DR; Meyer, WA; Ribaudo, HJ; Shikuma, CM; Tashima, KT; Webb, N; Yang, Y | 1 |
| Galli, M; Gervasoni, C; Grinelli, E; Ortu, M; Rusconi, S; Vigano, O | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Pajkrt, D; Scherpbier, HJ | 1 |
| Keiser, P; Nassar, N | 1 |
| Ait-Khaled, M; Brun-Vézinet, F; Collin, G; Craig, C; Damond, F; Delarue, S; Descamps, D | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Meyer, WA; Reichman, R; Ribaudo, HJ; Riddler, SA; Santana, J; Shikuma, C; Squires, KE | 1 |
| Kagan, RM; Lee, TS; Lewinski, MA; Lloyd, RM; Potts, SJ; Ross, L | 1 |
| Butler, K; Candeias, F; Castelli-Gattinara, G; Compagnucci, A; de Rossi, A; Della Negra, M; Feiterna-Sperling, C; Giaquinto, C; Gibb, DM; Green, H; Harper, L; Levy, J; Pillay, D; Saidi, Y; Walker, AS; Wintergerst, U | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Abad, J; Amorós-Quiles, I; Belda, A; Borrás-Blasco, J; Casterá, E; Rosique-Robles, D | 1 |
| Doerr, HW; Staszewski, S; Stürmer, M | 1 |
| Boom, WH; Charlebois, ED; Havlir, DV; Kayanja, HK; Lin, R; Mayanja-Kizza, H; Mugerwa, RD; Srikantiah, P; Walusimbi, MN; Whalen, CC | 1 |
| Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
| Barrufet, P; Crespo, M; Ferrer, E; Gatell, JM; Llibre, JM; Niubo, J; Podzamczer, D; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Cavassini, M; Furrer, H; Günthard, H; Hirschel, B; Opravil, M; Vernazza, P; von Wyl, V; Wolbers, M; Yerly, S | 1 |
| Díaz-Curiel, M; Fernández-Guerrero, ML; García-Delgado, R; Górgolas, M; Goyenechea, A; Rivas, P | 1 |
| Calza, L; Manfredi, R | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Galindo, MJ; Iribarren, J; Llibre, JM; Martinez-Picado, J; Negredo, E; Pérez-Alvarez, N; Schapiro, J | 1 |
| Gibert, CL; Grunfeld, C; Peng, G; Sharma, S; Shlay, JC | 1 |
| Haas, RH; Naviaux, RK; Saitoh, A; Salva, NG; Spector, SA; Wong, JK | 1 |
| Gazzard, BG; Jackson, A; Maitland, D; Mandalia, S; Moyle, GJ; Osorio, J | 1 |
| Cortes, C; Domingo, P; Ferrer, E; Gatell, JM; Gutierrez, M; Leon, A; Niubo, J; Pedrol, E; Podzamczer, D; Puig, T; Sanchez, P; Veloso, S | 1 |
| Andrews, M; Condoluci, DV; Luber, AD | 1 |
| Bánhegyi, D; Bannister, WP; Chiesi, A; Friis-Møller, N; Gargalianos, P; Kirk, O; Lundgren, JD; Mocroft, A; van Lunzen, J; Viard, JP | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Gerondelis, P; Irlbeck, DM; Lanier, E; Parkin, N; Ross, LL; Rouse, E; St Clair, MH; Trinh, L; Underwood, MR | 1 |
| Arndt, P; Clotet, B; Erkizia, I; Gorboulev, V; Koepsell, H; Martinez-Picado, J; Minuesa, G; Molina-Arcas, M; Pastor-Anglada, M; Volk, C | 1 |
| Hicks, CB | 1 |
| Ishikawa, H; Kaneko, S; Katayama, M; Matsuda, Y; Miyaji, K; Suzuki, K; Takamatsu, K | 1 |
| Moreno, V; Valencia, ME | 2 |
| Albrecht, H | 1 |
| Sax, PE | 1 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
| DeJesus, E; Hicks, CB; Lancaster, CT; Liao, Q; Pakes, GE; Pappa, KA; Ross, LL; Sension, MG; Sloan, LM; Wohl, DA | 1 |
| Arnaiz, JA; Arranz, JA; Arribas, JR; Barragán, P; Barrufet, P; Blanco, JL; Casas, E; Clotet, B; Cosín, J; Cruceta, A; Curran, A; Dalmau, D; Ferrer, E; Gatell, JM; González, A; Gutiérrez, F; Knobel, H; Llibre, JM; Loncá, M; Mallolas, J; Martínez, E; Miró, JM; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Sanz, J; Segura, F | 1 |
| Dauer, B; Gute, P; Khaykin, P; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Cohen, C; Dejesus, E; Elion, R; Gathe, JC; Ha, B; Hsu, RK; Lanier, R; Paulsen, D; Redfield, RR; Ross, L; Yau, L | 1 |
| Hogan, BK; Lewis, JS; Nierenberg, NE; Patterson, TF; Thompson, GR | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Kurtyka, D; Somboonwit, C; Velez, AP | 1 |
| Burke, A; Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Katundu, P; Kityo, C; Lyagoba, F; McCormick, A; Munderi, P; Ndembi, N; Pillay, D; Robertson, V; Walker, AS; Yirrell, DL | 1 |
| Asahchop, EL; Brenner, BG; Moisi, D; Ntemgwa, M; Toni, TA; Wainberg, MA | 1 |
| Bartlett, JA; Crump, JA; Kiwera, RA; Moon, AM; Ole-Nguyaine, S; Ramadhani, HO; Shao, HJ; Shao, JF; Thielman, NM; Uiso, LO; Woods, CW | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Barragán, P; Casamitjana, R; Deulofeu, R; Gatell, JM; Gutiérrez, F; Larrousse, M; Loncá, M; Mallolas, J; Martínez, E; Pérez, I; Pich, J; Podzamczer, D | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Babiker, AG; Darbyshire, JH; Gibb, DM; Gilks, CF; Grosskurth, H; Kityo, C; Mugyenyi, P; Munderi, P; Reid, A; Ssali, F; Walker, AS | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| Butini, L; Cirioni, O; Costantini, A; Giacometti, A; Montroni, M; Scalise, G | 1 |
| Bravenboer, B; Gisolf, EH; Groeneveld, PH; Hoepelman, AI; Koopmans, PP; Langebeek, N; Legrand, JC; Mulder, PG; Richter, C; Sprenger, HG; Ten Kate, RW; Ten Napel, CH; van der Werf, TS; Van Kasteren, ME; Vriesendorp, R | 1 |
| Baudewig, M; Becker, W; Blankenburg, M; Bogner, JR; Gorriahn, D; Jaeger, H; Mueller, MC; Stoll, M; Walli, R; Welte, R; Wolf, E | 1 |
| Bellos, N; Dejesus, E; Murphy, D; Patel, LG; Ross, LL; Shaefer, MS; Squires, KE; Wannamaker, PG; Young, B; Zhao, HH | 1 |
| Allegri, R; Amadasi, S; Carosi, G; Cristini, G; Gatti, F; Izzo, I; Mendeni, M; Motta, D; Paraninfo, G; Quiros-Roldan, E; Torti, C | 1 |
| Adkison, K; Bakeera-Kitaka, S; Burger, D; Gibb, DM; Kekitiinwa, A; Kendall, L; Mugyenyi, P; Musiime, V; Musoke, P; Odongo, F; Snowden, WB; Thomason, M; Walker, AS | 1 |
| Gold, WL; Koblic, PM; la Porte, CJ; Lee, TC | 1 |
| Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
| Gutiérrez, F; López, N; Masiá, M; Padilla, S; Ramos, JM; Robledano, C | 1 |
| Barragán, P; Bonet, R; Curran, A; Gatell, JM; Knobel, H; Loncá, M; Martínez, E; Negredo, E; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Bacheler, L; Dunn, DT; Gilks, C; Goodall, RL; Kaleebu, P; Kityo, C; Munderi, P; Pillay, D; Ranopa, M; Van Houtte, M | 1 |
| Rizzardini, G; Zucchi, P | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Aïssi, E; Ettahar, N; Huleux, T; Massongo, M; Melliez, H; Pasquet, A; Yazdanpanah, Y | 1 |
| Boom, WH; Charlebois, E; Havlir, DV; Lin, R; Mayanja-Kizza, H; Mugerwa, RD; Mugyenyi, P; Mupere, E; Nanteza, MW; Srikantiah, P; Whalen, CC | 1 |
| Amole, CD; Brisebois, C; Brown Ripin, DH; Essajee, S; Koehler, E; Levin, AD; Moore, MC; Sickler, JJ; Singh, IR | 1 |
| Hull, MW; Montaner, JS | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Bieniek, B | 1 |
| Frederiksen, CA; Langdahl, BL; Laursen, AL; Melchjorsen, J; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kityo, C; Mambule, I; Munderi, P; Reid, A; Ssali, F; Stöhr, W; Walker, AS | 1 |
| Angarano, G; Bellacosa, C; Graziano, G; Maggi, P; Montinaro, V; Pietanza, S; Strippoli, GF; Volpe, A | 1 |
| Adkison, KK; Bakeera-Kitaka, S; Burger, DM; Gibb, DM; Kasirye, P; Kekitiinwa, A; Kendall, L; Mhute, T; Nahirya-Ntege, P; Snowden, W; Ssenyonga, M; Tumusiime, C; Walker, AS | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Hoy, JF | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Caroleo, B; De Sarro, G; Di Mizio, G; Gallelli, L; Palleria, C; Staltari, O | 1 |
| Andriamanantena, D; Ficko, C; Flateau, C; Rapp, C; Reggad, A | 1 |
| Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M | 1 |
| Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Arribas, JR; Arrizabalaga, J; Bernardino, JI; Domingo, P; Martinez, E; Muñoz, J; Ocampo, A; Portilla, J; Pulido, F; Torres, R | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Antinori, A; Bansi, L; Boumis, E; Callegaro, A; Ceccherini-Silberstein, F; Dunn, D; Fearnhill, E; Forbici, F; Francisci, D; Maggiolo, F; Mussini, C; Nicastri, E; Palamara, G; Perno, CF; Sabin, C; Santoro, MM; Zazzi, M; Zoncada, A | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G | 1 |
| Antela, A; Clumeck, N; Duiculescu, D; Eberhard, A; Granier, C; Gutiérrez, F; Hocqueloux, L; Maggiolo, F; Min, S; Nichols, G; Pappa, K; Sandkovsky, U; Walmsley, SL; Wynne, B | 1 |
| Gisolf, EH; Langebeek, N; Legrand, J; Nieuwkerk, PT; Reiss, P; Richter, C; Sprangers, MA; Sprenger, HG | 1 |
| Gilks, CF; Goodall, RL; Gupta, RK; Kaleebu, P; Kityo, C; Lyagoba, F; Mugarura, L; Munderi, P; Pillay, D; Ranopa, M | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Kasirye, R; Kityo, C; Mambule, I; Mugyenyi, P; Pillay, D; Walker, AS | 1 |
| Abongomera, G; Arach, B; Asiimwe, AR; Cook, A; Gibb, DM; Kabamba, D; Kayiwa, J; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; Komunyena, J; Mirembe, G; Mulenga, V; Musiime, V; Nansubuga, C; Walker, SA; Wavamunno, P; Zangata, D | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Barreiro, P; De Mendoza, C; Fernandez-Montero, JV; Labarga, P; Soriano, V | 1 |
| Borok, M; Campbell, TB; Erlandson, KM; Fiorillo, S; Gudza, I; Gwanzura, L; Ndemera, B; Schooley, RT | 1 |
| Borland, J; Chen, S; Piscitelli, SC; Savina, P; Weller, S; Wynne, B | 1 |
| Carda-Broch, S; Casas-Breva, I; Esteve-Romero, J; Peris-Vicente, J; Villareal-Traver, M | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Moyle, G; Parisi, SG; Serpelloni, G | 1 |
| Blanche, S; Flynn, P; Giaquinto, C; Kakuda, TN; Komar, S; Lathouwers, E; Noguera-Julian, A; Opsomer, M; Van de Casteele, T; Welch, S | 1 |
| Commenges, D; Prague, M; Thiébaut, R | 1 |
| Albano, J; Gee, C; Koram, N; Tilson, H; Vannappagari, V | 1 |
| Bierman, W; Bravenboer, B; Gisolf, E; Groeneveld, P; Hoepelman, AI; Koopmans, PP; Langebeek, N; Legrand, JC; Mulder, PG; Richter, C; Sprenger, HG; Ten Kate, RW; Ten Napel, CH; van der Werf, Ts; Vriesendorp, R | 1 |
| A Rostad, C; Anderson, EJ; Camacho-Gonzalez, AF; Chakraborty, R; O Akerele, D; Spearman, P; Thompson, AB; Wynn, BA | 1 |
| Deeks, ED; Greig, SL | 1 |
| Córdoba Iturriagagoitia, A; Mitxelena Ezeiza, J; Santesteban Muruzábal, R; Yanguas Bayona, I | 1 |
| Henry, K; LaMarca, A; Ross, LL; Schneider, S; Shaefer, MS; Squires, KE; Tashima, K; Young, B; Zhao, HH | 1 |
| Bollen, P; Burger, D; Reiss, P; Schapiro, J | 1 |
| Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kelleher, AD; Losso, M; Madero, JS; Molina, JM; Moore, CL; Renjifo, B; Ruxrungtham, K; Teppler, H; Wolff, M; Wood, R | 1 |
| Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS | 1 |
| Bailly, F; Cotelle, P | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Gorantla, S; Lu, Y; Makarov, E; Senanayake, TH; Vinogradov, SV; Warren, G | 1 |
| Desai, A; Kadam, N; Raotole, N; Samanta, G; Tol, T | 1 |
| Cook, A; Gibb, DM; Kasirye, P; Mhute, T; Mugarura, L; Munjoma, M; Musiime, V; Nahirya-Ntege, P; Naidoo-James, B; Nankya, I; Ndashimye, E; Snowden, W; Spyer, MJ; Thomason, MJ; Thoofer, NK; Walker, AS | 1 |
| Bolduc, P; Cheeseman, SH; Colgate, E; Roder, N | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Cheret, A; Chirouze, C; Cotte, L; Cuzin, L; Flandre, P; Katlama, C; Pugliese, P; Rey, D | 1 |
| Chen, X; Cheng, Y; Guan, S; Han, L; Liu, Y; Wang, C | 1 |
| Andany, N; Gold, WL | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Ananworanich, J; Chokephaibulkit, K; Do, VC; Kerr, SJ; Kosalaraksa, P; Kurniati, N; Nguyen, LV; Prasitsuebsai, W; Singtoroj, T; Sohn, AH; Sudjaritruk, T; Teeraananchai, S; Truong, KH | 1 |
| Divi, RL; Gibbons, AT; Liu, Y; Poirier, MC; Shide, ED; Shim Park, E; Woodward, RA | 1 |
| Emerson, CR; Todd, S | 1 |
| Comi, L; Maggiolo, F | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| Bani-Sadr, F; Cabie, A; Cotte, L; de Boissieu, P; Delobel, P; Dramé, M; Garraffo, R; Huleux, T; Poizot-Martin, I; Raffi, F; Rey, D | 1 |
| Ascione, T; Boccia, G; Carleo, MA; De Caro, F; Pagliano, P; Tortora, F | 1 |
| Abach, J; Abongomera, G; Chabala, C; Colebunders, R; Cook, A; Gibb, DM; Kekitiinwa, A; Kityo, C; Lamorde, M; Mulenga, V; Musiime, V; Thomason, M; Walker, AS | 1 |
| Bhattarai, S; Fallon, JP; Galang, H; Habeeb, R; Johnson, TM; Shukla, PP; Sison, R; Slim, J | 1 |
| Akkina, R; Akkina, SR; Habu, Y; Hu, S; Kumar, DM; Neff, CP; Seki, T | 1 |
| Dunn, DT; Gilks, C; Goodall, RL; Gupta, RK; Kaleebu, P; Kityo, C; Mugarura, L; Munderi, P; Nkurunziza, P; Pattery, T; Pillay, D | 1 |
| Aboud, M; Brennan, C; Brinson, C; Granier, C; Hopking, J; Koteff, JA; Lake, JE; Logue, K; Santiago, L; Trottier, B; Wynne, B | 1 |
| Cassim, H; Gray, GE; Greeff, OBW; Lazarus, E; Liberty, A; Otwombe, K; Violari, A | 1 |
| Ceckova, M; Cerveny, L; Martinec, O; Ptackova, Z; Reznicek, J; Staud, F; Tupova, L | 1 |
| Aboud, M; Aylott, A; Belonosova, E; Buchanan, AM; Falcó, V; Hagins, DP; Man, CY; Orrell, C; Porteiro, N; Smith, KY; Vavro, C; Walmsley, S; Wynne, B | 1 |
| Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL | 1 |
| Berenguer Berenguer, J; Cenoz Gomis, S; Graefenhain, R; Lopez Sanchez-Cambronero, D; Losa García, JE; Martínez Sesmero, JM; Moreno Guillen, S; Parrondo Garcia, FJ | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Bigoloni, A; Carini, E; Castagna, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Nozza, S; Poli, A; Tambussi, G; Termini, R | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
| Iavarone, M; Maggioni, M; Merli, M; Orcese, C; Puoti, M; Rossotti, R | 1 |
| Abrams, EJ; Arpadi, S; Mogashoa, M; Mutiti, A; Nxele, M; Pepeta, L; Rivadeneira, ED; Sogaula, N; Teasdale, CA; Wang, C; Yuengling, KA | 1 |
| Chmelík, V; Chrdle, A; Jerhotová, Z; Linka, M; Vacík, M | 1 |
| Buchanan, AM; Casillas, L; Joshi, S; Shaik, JSB; Shreeves, T; Singh, RP; Skoura, N | 1 |
| Akakpo, AS; Bassowa, A; Dapam, AN; Kombaté, K; Laouali, AY; Mahamadou, G; Mensah, E; Mouhari-Toure, A; Pitché, P; Saka, B; Teclessou, JN | 1 |
| Carelli, M; Chiesi, S; Diani, E; Gibellini, D; Lanzafame, M; Lattuada, E; Nicole, S; Piacentini, D; Rizzardo, S; Vento, S | 1 |
| Badowski, ME; Michienzi, SM; Schriever, CA | 1 |
| Bailão, E; Cardoso, CG; Chen-Chen, L; Cunha, KS; de Jesus Silva Carvalho, C; de Moraes Filho, AV; Spanó, MA; Véras, JH | 1 |
| Rijnders, BJA; Rokx, C | 1 |
| Allavena, C; André, M; Avettand-Fènoël, V; Bernard, L; Billaud, E; Esnault, JL; Hocqueloux, L; Le Moal, G; Parienti, JJ; Prazuck, T; Raffi, F; Rey, D; Roncato-Saberan, M; Sunder, S; Valéry, A | 1 |
| Avihingsanon, A; Boettiger, D; Chaiwarith, R; Kantipong, P; Kiertiburanakul, S; Pongpech, N; Ross, J | 1 |
| Bragantini, D; Calza, L; Lanzafame, M; Lattuada, E; Nicolè, S; Rizzardo, S; Tacconelli, E | 1 |
| Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y | 1 |
| Barber, TJ | 1 |
| Halquist, MS; Hauser, KF; Jones, AM; Kashuba, ADM; Kim, WK; Knapp, PE; Leibrand, CR; Masuda, QN; McRae, M; Paris, JJ | 1 |
| Archary, M; Bobat, R; Hennig, S; LaRussa, P; Mcllleron, H; Sibaya, T; Wiesner, L | 1 |
| Al-Chalabi, A; Garcia Montojo, M; Gold, J; Kiernan, MC; Lombardi, V; Malaspina, A; Mathers, S; Mehta, PR; Nath, A; Norato, G; Rogers, ML; Rowe, DB; Santamaria, UA; van den Berg, LH; van Eijk, RPA; Vucic, S; Westeneng, HJ | 1 |
| Badowski, ME; Brizzi, MB; Chiampas, TD; Michienzi, SM; Patel, MC; Young, JD | 1 |
| Antinori, A; Barchi, E; Bonfanti, P; Bonora, S; Borghi, V; Cattelan, AM; D'Ettorre, G; Degli Antoni, A; Di Biagio, A; Focà, E; Francisci, D; Limonta, S; Maggiolo, F; Mussini, C; Nozza, S; Roncaglia, E; Rusconi, S; Segala, D | 1 |
| Boricic, I; Dimitrijevic, B; Dragovic, G; Jevtovic, D; Nikolic, K; Salemovic, D; Tomanovic, N | 1 |
| Amaro, C; Azurara, L; Miroux-Catarino, A; Monteiro, AF; Silva, L; Viana, I | 1 |
| Agulló, V; Fernández-González, M; García, JA; García-Abellán, J; Gutiérrez, F; Masiá, M; Padilla, S | 1 |
| Azran, C; Dahan, A; Elazary, R; Elinav, H; Gibori, R; Horwitz, E; Israel, S; Porat, D | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Jary, A; Lê, MP; Marcelin, AG; Peytavin, G; Wirden, M | 1 |
| Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Arrieta-Aldea, I; Brown, TT; Bujosa, D; Díez-Pérez, A; García-Giralt, N; González-Mena, A; Güerri-Fernández, R; Knobel, H; Lerma-Chippirraz, E; Pineda-Moncusi, M; Soldado-Folgado, J; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Adams-Huet, B; Bedimo, RJ; Maalouf, NM; Moore-Matthews, D; Nguyen, V; Poindexter, J | 1 |
| Axe, D; Ivos, M; Morris, JE | 1 |
| Batra, H; Chawla, H; Das, BK; Hussain, AW; Kabra, SK; Katpara, S; Kumar, S; Lodha, R; Luthra, K; Singh, R; Singh, S | 1 |
| Booth, J; Chowdary, P; Khurram, MA; Mohamed, IH; Shetty, S; Yaqoob, M | 1 |
| Acosta, S; Balogun, K; Guzman Lenis, MS; Mount, HT; Sarkar, A; Serghides, L | 1 |
| Hamzah, L; Post, FA | 1 |
| Lázaro, A; Mendoza, I; Torralba, M | 1 |
| Abdelzaher, AM; Elmaaty, AA; Hasan, MA; Serag, A; Tolba, EH | 1 |
| Baxi, SM; Choden, T; Desai, M; Dorjee, K; Hubbard, AE; Reingold, AL | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Oliveira, C; Giménez-Arufe, V; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Martínez-Pradeda, A; Mena-De-Cea, Á; Míguez-Rey, E; Rotea-Salvo, S; Vázquez-Rodríguez, P | 1 |
| Ang, JH; Ang, LW; Hoo, GS; Law, HL; Lee, CC; Leo, YS; Lim, ZC; Ng, OT; Teng, CB; Wong, CS | 1 |
| Bon, I; Calza, L; Fulgaro, C; Lazzarotto, T; Legnani, G; Verucchi, G; Viale, P | 1 |
| Andrieux-Meyer, I; Bekker, A; Capparelli, E; Cotton, MF; Cressey, R; Cressey, TR; du Toit, S; Groenewald, M; Kumar, M; Lallemant, M; Nielsen, J; Rabie, H; Salvadori, N; Than-In-At, K | 1 |
| Barbini, B; Campbell, L; Fox, J; Gilleece, Y; Ibrahim, F; Orkin, C; Post, FA; Samarawickrama, A; Tariq, S; Waters, L | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Christensen, BL; Tan, DH | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Ali, SM; Karoney, MJ; Kigen, G; Koech, MK | 1 |
| Benfield, T; Gerstoft, J; Hove, JD; Knudsen, A; Møller, S; Pedersen, KBH; Siebner, HR | 1 |
31 review(s) available for lamivudine and abacavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Coming therapies: abacavir.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.
Topics: Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Antiretroviral therapy-induced psychosis: case report and brief review of the literature.
Topics: Adult; Antipsychotic Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Female; Hallucinations; HIV Seropositivity; Humans; Lamivudine; Nevirapine; Psychoses, Substance-Induced; Zidovudine | 2003 |
Lamivudine/zidovudine/abacavir: triple combination tablet.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Treatment Outcome; Zidovudine | 2003 |
Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine | 2005 |
The impact of abacavir on lipids and lipodystrophy.
Topics: Acquired Immunodeficiency Syndrome; Cross-Sectional Studies; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; HIV Infections; Humans; Hyperlipidemias; Incidence; Lamivudine; Lipodystrophy; Male; Randomized Controlled Trials as Topic; Risk Assessment | 2005 |
Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.
Topics: Animals; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine | 2005 |
Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.
Topics: Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine | 2006 |
Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Treatment Outcome; Zidovudine | 2007 |
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Abacavir and lamivudine combination.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Drug Monitoring; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2009 |
Abacavir and lamivudine for the treatment of human immunodeficiency virus.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Dideoxynucleosides; HIV; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2011 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Maintenance Chemotherapy; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2013 |
Dolutegravir, abacavir and lamivudine as HIV therapy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2014 |
Virological efficacy of abacavir: systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2014 |
Triumeq--a 3-drug combination for HIV.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Medication Adherence; Mutation; Oxazines; Piperazines; Practice Guidelines as Topic; Pyridones; Reverse Transcriptase Inhibitors; Tablets | 2015 |
Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; RNA, Viral; Tablets | 2015 |
The preclinical discovery and development of dolutegravir for the treatment of HIV.
Topics: Animals; Dideoxynucleosides; Drug Combinations; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
Topics: Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets | 2016 |
Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Atovaquone; CD4 Lymphocyte Count; CD4-CD8 Ratio; COVID-19; Dideoxynucleosides; Female; Glucocorticoids; Graft Rejection; HIV Infections; HIV-1; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Middle Aged; Mycophenolic Acid; Pneumonia, Pneumocystis; Prednisolone; Raltegravir Potassium; RNA, Viral; SARS-CoV-2; Tacrolimus; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2022 |
121 trial(s) available for lamivudine and abacavir
| Article | Year |
|---|---|
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; HIV-1; Humans; Lamivudine; RNA, Viral; Time Factors; Viral Load; Zidovudine | 1998 |
Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Zidovudine | 1999 |
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
Topics: Cohort Studies; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients.
Topics: Acquired Immunodeficiency Syndrome; Alleles; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Resistance, Microbial; Female; HIV-1; Humans; Lamivudine; Male; Receptors, CCR5; Zidovudine | 2000 |
A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Confidence Intervals; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Growth; HIV-1; Humans; Infant; Lamivudine; Male; RNA, Viral; Zidovudine | 2001 |
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2001 |
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Microbial; Female; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Indinavir; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Survival Analysis; Therapeutic Equivalency; Viral Load; Zidovudine | 2001 |
Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
Topics: Absorption; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Eating; Fasting; Female; Half-Life; Humans; Lamivudine; Male; Mass Spectrometry; Middle Aged; Reverse Transcriptase Inhibitors; Therapeutic Equivalency; Zidovudine | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Half-Life; HIV Infections; HIV-1; Humans; Lamivudine; Male; Metabolic Clearance Rate; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2001 |
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Dideoxynucleosides; Digestive System; Drug Synergism; Ethnicity; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Subsets; Male; Pregnancy; Research Design; RNA, Viral; Sulfonamides; Treatment Refusal; Zidovudine | 2001 |
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Time Factors; Zidovudine | 2001 |
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
Triple nuke therapy--results after one year.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Zidovudine | 2002 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2002 |
Therapeutic vaccination in primary HIV infection, the Quest trial.
Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Defective Viruses; Dideoxynucleosides; Furans; HIV Infections; Humans; Immunotherapy, Active; Lamivudine; Lymphocyte Count; Sulfonamides; T-Lymphocyte Subsets; Vaccination; Vaccinia virus; Viral Load; Viral Vaccines; Viremia; Zidovudine | 2002 |
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV-1; Humans; Lamivudine; Lipids; Male; Prospective Studies; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2002 |
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Zidovudine | 2002 |
Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV-1; Humans; Infant; Lamivudine; RNA, Viral; Statistics, Nonparametric; Viral Load; Zidovudine | 2002 |
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; Drug Resistance, Viral; Female; HIV Infections; Humans; Hydroxyurea; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Nevirapine; Nucleosides; Phosphorylation; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV-1; Humans; Lamivudine; Nelfinavir; Phenotype; RNA, Viral; Zidovudine | 2002 |
Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Viral Load | 2003 |
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Zidovudine | 2003 |
Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
Topics: Adult; Body Composition; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Stavudine; Zidovudine | 2003 |
Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Patient Education as Topic; RNA, Viral; Zidovudine | 2003 |
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Chemistry, Pharmaceutical; Confidence Intervals; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Zidovudine | 2003 |
Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2003 |
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2003 |
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides | 2004 |
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organophosphates; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides | 2004 |
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2004 |
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; RNA, Viral; Stavudine; Thailand; Time Factors; Zidovudine | 2004 |
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; RNA; Surveys and Questionnaires; Therapeutic Equivalency; Treatment Outcome; Zidovudine | 2004 |
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome; Zidovudine | 2004 |
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Viral; Zidovudine | 2004 |
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.
Topics: Adult; Anti-HIV Agents; Body Composition; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Stavudine | 2005 |
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.
Topics: CD4 Lymphocyte Count; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; RNA, Viral; Viral Load; Zidovudine | 2005 |
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
Topics: Administration, Oral; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cross-Over Studies; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Netherlands; United Kingdom | 2005 |
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; RNA, Viral; Zidovudine | 2005 |
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2005 |
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Topics: Adenine; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Sequence Analysis, Protein; Tenofovir; Treatment Failure; Viral Load | 2005 |
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Time Factors; Treatment Failure | 2005 |
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Treatment Refusal; Viral Load | 2005 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).
Topics: Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Safety | 2006 |
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Topics: Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Messenger; Viral Load; Zidovudine | 2006 |
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Extremities; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Stavudine; Viral Load | 2007 |
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Body Composition; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Insulin Resistance; Lactic Acid; Lamivudine; Lipids; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Regression Analysis; RNA, Viral; Time Factors; Zidovudine | 2007 |
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Follow-Up Studies; Growth; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2008 |
Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
Topics: Adult; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Subcutaneous Fat; Zidovudine | 2008 |
Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chi-Square Distribution; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Viral Load | 2008 |
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Endpoint Determination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Spain; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2009 |
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Spain; Tenofovir; Treatment Failure; Treatment Outcome | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Mutation; Nevirapine; RNA, Viral; Uganda; Viral Load; Zidovudine | 2010 |
Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Pilot Projects; Tanzania; Tuberculosis; Viral Load; Zidovudine | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Uganda; Viral Load; Zidovudine | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2010 |
Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
Topics: Anti-HIV Agents; Child, Preschool; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2010 |
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Confidence Intervals; Cross-Over Studies; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Uganda | 2010 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Organophosphonates; Phospholipases A2; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 2011 |
A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Survival Analysis; Treatment Outcome; Tuberculosis, Pulmonary; Uganda; Young Adult; Zidovudine | 2011 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Tenofovir; Vascular Cell Adhesion Molecule-1 | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Glomerulus; Lamivudine; Male; Nevirapine; Organophosphonates; Risk Factors; Tenofovir; Time Factors; Zidovudine | 2011 |
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Absorptiometry, Photon; Adenine; Adult; Bone Density; Bone Remodeling; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Infant; Lactation; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2013 |
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Atrophy; Body Composition; Chemistry, Pharmaceutical; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Intention to Treat Analysis; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Young Adult | 2013 |
A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Netherlands; Odds Ratio; Patient Satisfaction; Quality of Life; Ritonavir; Zidovudine | 2014 |
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Nevirapine; Viral Load; Viremia; Zidovudine | 2014 |
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Probability; Retrospective Studies; RNA, Viral; Tenofovir; Uganda; Viral Load; Zidovudine | 2014 |
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipid Metabolism; Lipodystrophy; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nevirapine; Stavudine; Triglycerides; Viral Load; Zidovudine | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Dideoxynucleosides; Disease Progression; Female; Herpesvirus 8, Human; HIV-1; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Pilot Projects; Prospective Studies; RNA, Viral; Sarcoma, Kaposi; Survival Analysis; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Zidovudine; Zimbabwe | 2014 |
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Dideoxynucleosides; Dietary Fats; Drug Combinations; Female; Food-Drug Interactions; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Therapeutic Equivalency; Vaginal Creams, Foams, and Jellies; Young Adult | 2014 |
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Topics: Adolescent; Anemia; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Nausea; Neutropenia; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Time Factors; Viral Load; Vomiting; Zidovudine | 2014 |
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Topics: Adult; Aged; Anti-HIV Agents; Belgium; CD4 Lymphocyte Count; Clinical Protocols; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Netherlands; Prospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2015 |
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Ritonavir; South Australia; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets; Uganda; Zambia; Zidovudine | 2016 |
Once vs twice-daily abacavir and lamivudine in African children.
Topics: Adolescent; Africa; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Immune Reconstitution; Infant; Lamivudine; Male; Medication Adherence; Sustained Virologic Response; Treatment Outcome | 2016 |
Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Canada; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Outcome; United States; Viral Load | 2017 |
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Dideoxynucleosides; Drug Combinations; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Middle Aged; Minerals; Oxazines; Piperazines; Pyridones; Tablets; Water; Young Adult | 2018 |
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; DNA, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Viral Load; Young Adult | 2018 |
Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Topics: Adult; Anti-HIV Agents; Confidence Intervals; Dideoxynucleosides; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.
Topics: Anti-HIV Agents; Biological Availability; Body Weight; Child; Child Nutrition Disorders; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Biological; Nutritional Support; Severity of Illness Index; South Africa; Time Factors; Time-to-Treatment; Treatment Outcome; Viral Load | 2019 |
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2019 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Infant, Newborn; Lamivudine; Lopinavir; Ritonavir | 2022 |
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Middle Aged; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open
Topics: Body Composition; Body Weight; Cardiovascular Diseases; Denmark; HIV Infections; Humans; Lamivudine; Quality of Life | 2023 |
219 other study(ies) available for lamivudine and abacavir
| Article | Year |
|---|---|
The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Lamivudine; Models, Molecular; Molecular Conformation; Mutation; Nucleosides; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tyrosine | 2003 |
Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Drug Resistance, Viral; Ducks; Hepatitis B virus; Humans; Lamivudine; Mutation; Pyrimidine Nucleosides; Structure-Activity Relationship; Virus Replication | 2006 |
Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Topics: Animals; Antiviral Agents; Cell Line; Cell Line, Tumor; Chlorocebus aethiops; Deoxyribose; Drug Resistance, Viral; Ducks; Hepatitis B virus; Humans; Lamivudine; Molecular Mimicry; Mutation; Pyrimidine Nucleosides; Structure-Activity Relationship; Virus Replication | 2006 |
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cell Line; Dogs; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2007 |
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
Topics: Anti-HIV Agents; HeLa Cells; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Ducks; Hepatitis B virus; Hepatitis B Virus, Duck; Hepatocytes; Humans; Lamivudine; Mutation; Pyrimidine Nucleosides; Stereoisomerism; Structure-Activity Relationship; Virus Replication | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
Topics: Anti-HIV Agents; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Molecular Structure; Nucleosides; Prodrugs; Structure-Activity Relationship | 2013 |
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
Topics: Acyclovir; Animals; Antiviral Agents; Betulinic Acid; Chlorocebus aethiops; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; Pentacyclic Triterpenes; Triterpenes; Vero Cells; Virus Replication | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Virus Replication; Zidovudine | 1998 |
[HIV, hepatitis, influenza: new antiviral agents].
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiviral Agents; Child; Clinical Trials as Topic; Dideoxynucleosides; Enzyme Inhibitors; Guanidines; Hepatitis B; Humans; Influenza, Human; Lamivudine; Neuraminidase; Pyrans; Reverse Transcriptase Inhibitors; Sialic Acids; Zanamivir | 1999 |
Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
Topics: AIDS Dementia Complex; Animals; Cells, Cultured; Didanosine; Dideoxynucleosides; Disease Models, Animal; HIV-1; Humans; Lamivudine; Male; Mice; Mice, SCID; Monocytes; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zidovudine | 2000 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
Are nelfinavir-containing regimens effective as second-line triple therapy?
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine | 2000 |
[First HIV triple therapy with one tablet].
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2000 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Disease Reservoirs; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Stavudine; Viral Load; Zidovudine | 2000 |
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Furans; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Neutralization Tests; Ritonavir; Sulfonamides; Zidovudine | 2000 |
Intensification of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression.
Topics: Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2000 |
Trizivir on the market.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 2001 |
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Epstein-Barr Virus Infections; Flow Cytometry; Furans; Genotype; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lamivudine; Longitudinal Studies; Male; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR5; Sulfonamides; Time Factors; Zidovudine | 2001 |
Triple-drug tablet approved for HIV infection.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Dideoxynucleosides; Drug Combinations; Drug Labeling; HIV Infections; Humans; Lamivudine; Tablets; Zidovudine | 2001 |
Phase III trials for new PI.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Randomized Controlled Trials as Topic; Sulfonamides | 2001 |
New drugs: amprenavir and abacavir.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Lamivudine; Lipodystrophy; Oxazines; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1998 |
A new HAART on the horizon says the proof is in the potency.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; Patient Compliance; Pregnancy; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Nukes alone.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; France; HIV Infections; Humans; Lamivudine; Zidovudine | 1999 |
Choosing which nuke to use first.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
[Acceptance of antiretroviral therapy. HIV-infected patients assess convenient triple combination].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Patient Acceptance of Health Care; Patient Compliance; Zidovudine | 2001 |
Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.
Topics: Animals; Anti-HIV Agents; Cats; Cell Line; Dideoxynucleosides; Drug Synergism; Drug Therapy, Combination; Feline Acquired Immunodeficiency Syndrome; Humans; Hydroxyurea; Immunodeficiency Virus, Feline; Kidney; Lamivudine; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 2002 |
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.
Topics: Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Microbial; Gene Frequency; Genotype; HIV; Humans; Lamivudine; Microbial Sensitivity Tests; Zidovudine | 2002 |
Antiretroviral rounds. A very discordant response.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Practice Patterns, Physicians'; Reverse Transcriptase Inhibitors; Stavudine; Viral Load | 2002 |
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; CD48 Antigen; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dideoxynucleosides; Drug Evaluation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; London; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Follow-Up Studies; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Virus Replication; Zidovudine | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Viral Load; Zidovudine | 2003 |
Chronic cough induced by abacavir apart from a context of hypersensitivity.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chronic Disease; Cough; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Middle Aged; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Rhinitis; Sputum; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2002 |
FDA notifications. Product tampering labels Ziagen as Combivir.
Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Drug Combinations; Drug Labeling; Humans; Lamivudine; United States; United States Food and Drug Administration; Zidovudine | 2002 |
Abacavir arm stopped in clinical trial.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Viral Load; Zidovudine | 2003 |
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Topics: Acyclovir; Antiviral Agents; Base Sequence; Deoxyguanosine; Dideoxynucleosides; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Humans; Lamivudine; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Transfection; Tumor Cells, Cultured; Virus Replication | 2003 |
Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Dideoxynucleosides; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Salvage Therapy; Zidovudine | 2003 |
[Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone].
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Male; Methadone; Opioid-Related Disorders; Reverse Transcriptase Inhibitors; Substance Withdrawal Syndrome; Treatment Outcome; Zidovudine | 2003 |
Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Cell Line; Dideoxynucleosides; Human T-lymphotropic virus 1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication; Zalcitabine; Zidovudine | 2003 |
[Hypersensitive reaction to abacavir or syphilitic hepatitis?].
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Ethylenediamines; HIV Seropositivity; Humans; Lamivudine; Male; Syphilis; Zidovudine | 2003 |
Warning issued on non-response rates.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
Topics: Acidosis, Lactic; Adult; Alanine Transaminase; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Zidovudine | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Oxazines; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Topics: Adenine; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Failure of combination abacavir + tenofovir + lamivudine (3TC).
Topics: Adenine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Abandon Trizivir when it's working well? A rebuttal.
Topics: Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Comment: Reasons for early abacavir discontinuation in HIV-infected patients.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Treatment Refusal; Zidovudine | 2004 |
Early nonresponse for tenofovir regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2003 |
Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.
Topics: Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; Epilepsy, Complex Partial; HIV Infections; Humans; Lamivudine; Male; Valproic Acid; Zidovudine | 2004 |
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
Topics: Adenine; Anti-HIV Agents; Cloning, Molecular; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Genotype; HIV; HIV Reverse Transcriptase; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; European Union; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pilot Projects; Safety; Tenofovir; Treatment Failure; Viral Load | 2004 |
Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Dideoxynucleosides; Drug Evaluation, Preclinical; HIV Core Protein p24; HIV Infections; Humans; Immunotoxins; Lamivudine; Phytohemagglutinins; Receptors, Interleukin-2; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Sweet's syndrome following abacavir therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Sweet Syndrome; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
[Valuable combination partner. Great benefit for therapy naive patients].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Multicenter Studies as Topic; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Genes, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Point Mutation; Retrospective Studies; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Tenofovir use in a patient with a severe renal impairment.
Topics: Adenine; Adult; Diabetic Nephropathies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2004 |
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Apoptosis; Cell Differentiation; Didanosine; Dideoxynucleosides; HIV-1; HIV-Associated Lipodystrophy Syndrome; Lamivudine; Lipid Metabolism; Mice; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2004 |
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Zidovudine | 2004 |
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Brain; CD4 Lymphocyte Count; Cidofovir; Cytosine; Dideoxynucleosides; Encephalitis; False Negative Reactions; Fatal Outcome; Humans; Immunocompromised Host; Indinavir; JC Virus; Lamivudine; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Organophosphonates; Substance Abuse, Intravenous; Time Factors; Virus Activation; Zidovudine | 2004 |
[Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Costs and Cost Analysis; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Patient Compliance; Retrospective Studies; Zidovudine | 2004 |
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Drug Stability; HIV; HIV Infections; Humans; Lamivudine; Quality Control; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stavudine; Zidovudine | 2005 |
Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
GlaxoSmithKline receives European approval for Kivexa.
Topics: Adolescent; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Approval; Drug Combinations; Europe; Humans; Lamivudine | 2005 |
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Topics: Adenine; Anti-HIV Agents; Cell Line; Dideoxynucleosides; Drug Interactions; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Organophosphonates; Tenofovir | 2005 |
Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.
Topics: Adenine; Anti-HIV Agents; Cell Line, Transformed; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Tenofovir | 2005 |
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2005 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Hypersensitivity; Lamivudine; Male; Patient Compliance; Retrospective Studies; Spain; Treatment Failure; Zidovudine | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Investigating new antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Pilot Projects; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Patient Acceptance of Health Care; Patient Compliance; Prospective Studies; Risk Assessment; Sex Factors; Single-Blind Method; Treatment Outcome; United Kingdom; Viral Load | 2006 |
Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Controlled Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Oxazines; Prospective Studies; Time Factors; Treatment Outcome; Zidovudine | 2006 |
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Genome, Bacterial; HIV-1; Humans; In Vitro Techniques; Lamivudine; Mutagenesis, Site-Directed; Mutation; Organophosphonates; Selection, Genetic; Sequence Analysis, DNA; Tenofovir | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure | 2006 |
The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine Kinase; Dideoxynucleosides; Drug Resistance, Neoplasm; Humans; Lamivudine; Leukemia, Lymphoid; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phenotype; T-Lymphocytes; Thymidine Kinase; Zidovudine | 2006 |
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Resistance, Multiple, Viral; Genotype; Glutamic Acid; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lysine; Mutagenesis, Site-Directed; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir; Thymine Nucleotides; Zidovudine | 2007 |
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2006 |
Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Phosphates; Reference Standards; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Zidovudine | 2007 |
Anti-HIV agents. Abacavir--as good as AZT?
Topics: Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Hypersensitivity; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral | 2007 |
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child Development; Child, Preschool; Cholesterol; Cohort Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Oxazines; Patient Compliance; Prospective Studies; Treatment Outcome | 2007 |
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Viral Load | 2006 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Hair loss induced by lopinavir-ritonavir.
Topics: Adult; Alkynes; Alopecia; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Probability; Pyrimidinones; Ritonavir | 2007 |
Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Tuberculosis, Pulmonary; Zidovudine | 2007 |
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Spain; Species Specificity; Treatment Failure; Viral Load | 2007 |
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Genes, MDR; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Reverse Transcriptase Inhibitors; RNA, Viral; Switzerland; Treatment Failure; Viral Load; Zidovudine | 2007 |
Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Case-Control Studies; Dideoxynucleosides; Femur Neck; HIV Infections; Humans; Lamivudine; Lopinavir; Lumbar Vertebrae; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; Zidovudine | 2008 |
New formulations approved for children.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Child; Child, Preschool; Dideoxynucleosides; Drug Approval; Drug Combinations; European Union; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Thymidine; Viral Load; Zidovudine | 2008 |
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
Topics: Cell Proliferation; Cells, Cultured; Dideoxynucleosides; DNA, Mitochondrial; Humans; Lamivudine; Muscle Fibers, Skeletal; Muscle, Skeletal; Myoblasts; Nucleosides; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Mitochondrial; Stavudine; Zidovudine | 2008 |
CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Humans; Lamivudine; Middle Aged; Organophosphonates; Tenofovir | 2008 |
Incidence of abacavir hypersensitivity reactions in euroSIDA.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Poisson Distribution; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2008 |
FDA notifications. Generic abacavir and lamivudine combo approved.
Topics: Dideoxynucleosides; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2008 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Phenotype; Plasmids; Tenofovir; Viral Load | 2009 |
Generic lamivudine and abacavir approved.
Topics: Anti-HIV Agents; Child; Dideoxynucleosides; Drug Approval; Drugs, Generic; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2008 |
Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.
Topics: Animals; Anti-HIV Agents; Binding Sites; Biological Transport, Active; CHO Cells; Cricetinae; Cricetulus; Dideoxynucleosides; Drug Interactions; Humans; Kinetics; Lamivudine; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Reverse Transcriptase Inhibitors; Transfection; Zidovudine | 2009 |
FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.
Topics: Dideoxynucleosides; Drug Approval; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2009 |
Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2009 |
Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection.
Topics: Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Electrochemical Techniques; Fluorescence; Humans; Lamivudine; Linear Models; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Water; Zidovudine | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2008 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.
Topics: Anti-HIV Agents; Antifungal Agents; Cerebrospinal Fluid; Dideoxynucleosides; Drug Monitoring; HIV Infections; Humans; Interferon-gamma; Lamivudine; Male; Meningitis, Cryptococcal; Pyrimidines; Ritonavir; Serum; Triazoles; Voriconazole; Young Adult | 2010 |
FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
Topics: Dideoxynucleosides; Drug Approval; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration; Zidovudine | 2009 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
[Durability and tolerability of long-term nevirapine-based HAART].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Comorbidity; Dideoxynucleosides; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lipids; Liver Function Tests; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Viral Load; Young Adult; Zidovudine | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany.
Topics: Anti-HIV Agents; Costs and Cost Analysis; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Germany; HLA-B Antigens; Hospitalization; Humans; Lamivudine; Mass Screening; Retrospective Studies; Reverse Transcriptase Inhibitors | 2010 |
The impact of gender and anchor drugs on TDF renal toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Lamivudine; Male; Organophosphonates; Sex Factors; Tenofovir | 2010 |
Medication-based urolithiasis and atazanavir.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Uric Acid; Urinary Calculi; Urolithiasis | 2011 |
Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; HIV Seropositivity; Humans; Lamivudine; Longitudinal Studies; Male; Organophosphonates; Parathyroid Hormone; Tenofovir; Vitamin D; Vitamin D Deficiency | 2012 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Ribavirin; Zidovudine | 2012 |
[Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].
Topics: Abscess; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Axilla; Clarithromycin; Darunavir; Dideoxynucleosides; Enfuvirtide; Ethambutol; HIV Envelope Protein gp41; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Isoniazid; Lamivudine; Lymph Node Excision; Lymphadenitis; Male; Mycobacterium avium-intracellulare Infection; Peptide Fragments; Pyrazinamide; Rifampin; Ritonavir; Streptomycin; Sulfonamides | 2011 |
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Developing Countries; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Health Planning; Health Services; HIV Infections; Humans; Lamivudine; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2011 |
Optimizing initial therapy for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2011 |
[Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; CD4 Lymphocyte Count; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Neoplasms; HIV Seropositivity; Humans; Intestine, Small; Lamivudine; Lymphoma, AIDS-Related; Male; Pyrrolidinones; Raltegravir Potassium; Remission Induction; Viral Load | 2011 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; Glutathione Transferase; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Lamivudine; Male; Middle Aged; Mitochondria; Organophosphonates; Tenofovir; Time Factors | 2012 |
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
Topics: Administration, Oral; Antirheumatic Agents; Chemistry, Pharmaceutical; Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Solutions; Tablets; Therapeutic Equivalency; Zidovudine | 2012 |
A case of adverse drug reaction induced by dispensing error.
Topics: Acute Kidney Injury; Aged; Antiretroviral Therapy, Highly Active; Asthenia; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Male; Medication Errors | 2012 |
[Acute hemolytic anemia in an HIV patient after inhalation of amyl nitrite].
Topics: Administration, Inhalation; Adult; Amyl Nitrite; Anemia, Hemolytic; Anti-HIV Agents; Diagnosis, Differential; Dideoxynucleosides; HIV Infections; Humans; Illicit Drugs; Inhalant Abuse; Iraq; Lamivudine; Male; Travel; Zidovudine | 2012 |
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Retrospective Studies; Risk Factors; South Africa; Stavudine; Time Factors | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2013 |
A micellar liquid chromatography method for the quantification of abacavir, lamivudine and raltegravir in plasma.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Dideoxynucleosides; Lamivudine; Micelles; Plasma; Pyrrolidinones; Raltegravir Potassium; Sodium Dodecyl Sulfate | 2014 |
[Mathematical dynamical models for personalized medicine].
Topics: Anti-HIV Agents; Azacitidine; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; HIV Infections; HIV-1; HLA-B Antigens; Humans; Lamivudine; Models, Theoretical; Precision Medicine; Receptors, CCR5; Reverse Transcriptase Inhibitors; Virus Attachment | 2014 |
Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Prospective Studies; Young Adult | 2015 |
Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration.
Topics: Adolescent; Anti-HIV Agents; Black or African American; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Pancreatitis, Acute Necrotizing; Piperazines; Pyridones | 2015 |
[Cutaneous CD8+ T-cell lymphoma. Regression after HIV antiviral triple therapy].
Topics: Alopecia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Clone Cells; Dideoxynucleosides; Drug Therapy, Combination; Humans; Immunophenotyping; Lamivudine; Lymphoma, AIDS-Related; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Ritonavir | 2015 |
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Dideoxynucleosides; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir | 2015 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.
Topics: Animals; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Hep G2 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mice; Nanogels; Polyethylene Glycols; Polyethyleneimine; Polylysine; Reverse Transcriptase Inhibitors; Zidovudine | 2015 |
A simultaneous determination of related substances by high performance liquid chromatography in a drug product using quality by design approach.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; Lamivudine; Monte Carlo Method; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Temperature | 2016 |
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
Topics: Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Lamivudine; Male; Propensity Score; Prospective Studies; Risk Assessment; Tenofovir; Treatment Failure; Viral Load | 2016 |
Zidovudine, abacavir and lamivudine increase the radiosensitivity of human esophageal squamous cancer cell lines.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Dideoxynucleosides; DNA Damage; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lamivudine; Radiation Tolerance; Radiation-Sensitizing Agents; Telomerase; Telomere; Zidovudine | 2016 |
Single-tablet antiretroviral treatment (once daily).
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Drug Interactions; Drug Resistance, Viral; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Mental Disorders; Oxazines; Piperazines; Pyridones; Viral Load | 2016 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Indonesia; Lamivudine; Male; Prospective Studies; Ritonavir; Thailand; Treatment Outcome; Vietnam; Viral Load; Zidovudine | 2016 |
Mitochondrial compromise in 3-year old patas monkeys exposed in utero to human-equivalent antiretroviral therapies.
Topics: Animals; Anti-HIV Agents; Bone Marrow Cells; Brain; Dideoxynucleosides; DNA, Mitochondrial; Drug Therapy, Combination; Erythrocebus patas; Female; Gestational Age; Heart; Lamivudine; Mitochondria; Mitochondria, Heart; Oxygen Consumption; Pregnancy; Prenatal Exposure Delayed Effects; Zidovudine | 2016 |
A severe hypersensitivity reaction to abacavir following re-challenge.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; HLA-B Antigens; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2017 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
Topics: Adult; Dideoxynucleosides; Drug Therapy, Combination; Female; France; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2016 |
HIV positive patient with HSV-2 encephalitis: case report.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Substitution; Encephalitis, Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Rilpivirine; Ritonavir; Virus Replication | 2016 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Nevirapine; Randomized Controlled Trials as Topic; Stavudine; Surveys and Questionnaires; Uganda; Zambia; Zidovudine | 2017 |
A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy.
Topics: Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Disease Models, Animal; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-2; Humans; Lamivudine; Mice; Mice, Inbred BALB C; Oxazines; Piperazines; Pyridones | 2017 |
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2017 |
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Topics: Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Retrospective Studies; Ritonavir; South Africa; Stavudine; Treatment Outcome; Viral Load | 2017 |
MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Caco-2 Cells; Cell Line; Cell Line, Tumor; Dideoxynucleosides; Dogs; Drug Interactions; Humans; Intestinal Absorption; Lamivudine; Madin Darby Canine Kidney Cells; Male; Membrane Transport Proteins; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rilpivirine | 2017 |
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2017 |
Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; Drug Compounding; Female; Heterocyclic Compounds, 3-Ring; HIV Seropositivity; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Spain | 2017 |
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Linear Models; Male; Middle Aged; Retrospective Studies; Rilpivirine; Time Factors; Treatment Failure; Viral Load | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cholestasis; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2018 |
HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Topics: Adult; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; Health Resources; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Medication Adherence; Ritonavir; South Africa; Viral Load | 2018 |
Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression.
Topics: Adenocarcinoma; Anti-Retroviral Agents; Dideoxynucleosides; Gastric Outlet Obstruction; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Intubation, Gastrointestinal; Lamivudine; Male; Middle Aged; Oxazines; Parenteral Nutrition; Piperazines; Pyridones; Stomach Neoplasms; Sustained Virologic Response; Treatment Outcome | 2019 |
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Mucositis; Nevirapine; Reverse Transcriptase Inhibitors; Stevens-Johnson Syndrome | 2018 |
Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Renal Dialysis; Tablets; Treatment Outcome; Viral Load | 2019 |
Toxicity and genotoxicity induced by abacavir antiretroviral medication alone or in combination with zidovudine and/or lamivudine in Drosophila melanogaster.
Topics: Animals; Anti-HIV Agents; Dideoxynucleosides; DNA Damage; Drosophila melanogaster; Drug Synergism; Lamivudine; Mutation; Recombination, Genetic; Zidovudine | 2019 |
Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives?
Topics: Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Prediction Model of Pre-treatment HIV RNA Levels in Naïve Thai HIV-infected Patients: Application for Resource-limited Settings.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Thailand | 2018 |
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Treatment Outcome; Triglycerides | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Capillary Permeability; Corpus Striatum; Dextrans; Dideoxynucleosides; Female; Fluorescein-5-isothiocyanate; Heterocyclic Compounds, 3-Ring; Hippocampus; HIV Infections; HIV-1; Lamivudine; Mice; Mice, Transgenic; Models, Biological; Morphine; Neurocognitive Disorders; Oxazines; Piperazines; Pyridones; tat Gene Products, Human Immunodeficiency Virus | 2019 |
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.
Topics: Adolescent; Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Cohort Studies; Dideoxynucleosides; Disease Progression; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Young Adult | 2019 |
Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Illinois; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prisoners; Prisons; Pyridones; Retrospective Studies; Treatment Outcome | 2019 |
Severe hepatotoxicity induced by efavirenz in a treatment-naïve, low body mass index HIV-infected, female patient with no hepatitis and other virus co-infections.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Chemical and Drug Induced Liver Injury; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2019 |
Pediatric Kaposi's sarcoma associated with immune reconstitution inflammatory syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Dideoxynucleosides; Drug Therapy, Combination; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Ritonavir; Sarcoma, Kaposi | 2020 |
Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Piperazines; Pyridones; RNA Stability; RNA, Viral; Sexual and Gender Minorities; Viral Load | 2020 |
Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
Topics: Adult; Anti-Retroviral Agents; Bariatric Surgery; Dideoxynucleosides; Drug Monitoring; Gastrectomy; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Obesity, Morbid; Oxazines; Piperazines; Pyridones | 2020 |
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
Topics: Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones | 2020 |
Changes in bone microarchitecture with abacavir--lamivudine versus tenofovir disoproxil fumarate--emtricitabine in adults living with HIV.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Emtricitabine; Fractures, Bone; HIV Infections; Humans; Incidence; Lamivudine; Osteoporotic Fractures; Tenofovir | 2020 |
Recurrent ocular syphilis in a patient living with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Dideoxynucleosides; Eye Infections, Bacterial; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Neurosyphilis; Oxazines; Penicillin G; Piperazines; Pyridones; Syphilis; Syphilis Serodiagnosis; Treatment Outcome; Treponema pallidum; Uveitis; Visual Acuity | 2020 |
Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
Topics: Anti-HIV Agents; Antibodies, Neutralizing; Antibody-Dependent Cell Cytotoxicity; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; HIV Antibodies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Ritonavir; Viral Load; Zidovudine | 2020 |
In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Developmental Disabilities; Dideoxynucleosides; Emtricitabine; Exploratory Behavior; Female; Fetal Growth Retardation; Growth Disorders; Hand Strength; HIV Protease Inhibitors; Homing Behavior; Lamivudine; Male; Mice; Mice, Inbred C57BL; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Reflex, Abnormal; Reflex, Righting; Sensation Disorders; Taxis Response; Tenofovir | 2020 |
Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir.
Topics: Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin; Lamivudine; Menopause; Nitriles; Oxazines; Piperazines; Pyridones; Pyrimidines; Raltegravir Potassium; Waist Circumference; Weight Gain | 2021 |
Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Viral Load | 2022 |
Analysis of the ternary antiretroviral therapy dolutegravir, lamivudine and abacavir using UV spectrophotometry and chemometric tools.
Topics: Calibration; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Least-Squares Analysis; Oxazines; Piperazines; Pyridones; Spectrophotometry; Spectrophotometry, Ultraviolet | 2022 |
Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Myocardial Infarction; Tenofovir; United States | 2021 |
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Topics: Anti-HIV Agents; Cobicistat; Creatinine; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine | 2023 |
Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
Topics: Anti-HIV Agents; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Rilpivirine; Singapore | 2021 |
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
Topics: Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2022 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Kidney; Lamivudine; Retrospective Studies | 2023 |
Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; Humans; Kenya; Lamivudine; Vomiting | 2022 |